Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 197.40M -73.2% |
| Revenue (ttm) | 83.30M -61.3% |
| Net Income | -75.00M |
| EPS | -3.95 |
| Shares Out | 20.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,877 |
| Open | 9.58 |
| Previous Close | 9.58 |
| Day's Range | 9.42 - 10.00 |
| 52-Week Range | 5.42 - 36.73 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated... [Read more]
Financial Performance
Financial StatementsNews
Xbrane Biopharma AB Earnings Call Transcript: Q2 2026
Ximluci maintained a 7% market share in Europe with resumed shipments and SEK 46.8 million in Q2 revenue. Production cost reductions are expected to take effect from mid-2027, and FDA approval for U.S. launch is pending. Cash position is sufficient for ongoing operations.
Xbrane Biopharma AB Quarterly report: Q2 2026
Xbrane Biopharma AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
Xbrane Biopharma AB Slides: Q2 2026
Xbrane Biopharma AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q1 2026
Ximluci achieved SEK 17.3 million in Q1 revenue and 8% market share in Europe, with ongoing cost reduction efforts amid price competition. Xdivane development is on track, with new financing terms and a potential SEK 10 billion profit sharing over 10 years.
Xbrane Biopharma AB Quarterly report: Q1 2026
Xbrane Biopharma AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
Xbrane Biopharma AB Slides: Q1 2026
Xbrane Biopharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q4 2025
Ximluci saw strong year-over-year growth and profit contribution, but faces increased price pressure and competition in Europe. Cost reduction measures and FDA resubmission are key focuses, while Xdivane development remains on track for a 2027 US launch.
Xbrane Biopharma AB Annual report: Q4 2025
Xbrane Biopharma AB has published its Q4 2025 annual report on February 20, 2026.
Xbrane Biopharma AB Quarterly report: Q4 2025
Xbrane Biopharma AB has published its Q4 2025 quarterly earnings report on February 20, 2026.
Xbrane Biopharma AB Slides: Q4 2025
Xbrane Biopharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 20, 2026.
Xbrane Biopharma AB Earnings Call Transcript: Q3 2025
Ximluci maintained stable market share and revenue in Q3, with resumed shipments and a strong cash position following a directed share issue. FDA approval for U.S. launch is delayed, while Xdivane development progresses on track for a 2028 launch.
Xbrane Biopharma AB Quarterly report: Q3 2025
Xbrane Biopharma AB has published its Q3 2025 quarterly earnings report on October 24, 2025.
Xbrane Biopharma AB Slides: Q3 2025
Xbrane Biopharma AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 24, 2025.
Xbrane Biopharma AB Transcript: Investing in Life Science 2025
Biosimilars are gaining market share due to regulatory changes and growing acceptance. Ximluci, a Lucentis biosimilar, is performing well in Europe and preparing for a U.S. launch, while Xdivane, an Opdivo biosimilar, targets a 2029 launch. Recent restructuring and partnerships have improved financial stability and global reach.